01 Increasing adoption of artificial intelligence (AI) The tissue diagnostics market trends are being shaped by the increasing adoption of artificial intelligence (AI), digital pathology, and precision medicine to improve cancer diagnosis and treatment. Healthcare providers are investing in advanced tissue testing technologies that deliver faster, more accurate, and standardized diagnostic results. The growing demand for biomarker-based testing and companion diagnostics is also supporting the expansion of personalized cancer care across hospitals and diagnostic laboratories.
02 Recent Instances and Facts April 2025: Roche received the U.S. FDA Breakthrough Device Designation for its AI-powered companion diagnostic for non-small cell lung cancer, marking a major advancement in AI-assisted tissue diagnostics and precision oncology. 2026: The U.S. FDA continued authorizing new tissue-based companion diagnostic tests for targeted cancer therapies, enabling physicians to match patients with personalized treatments for cancers such as lung, ovarian, prostate, and gastrointestinal cancers. These developments indicate that AI integration, digital pathology, and precision oncology will remain the key tissue diagnostics market trends driving innovation and improving patient outcomes worldwide.
01 Growing adoption of precision medicine The tissue diagnostics market is expanding due to the rising global burden of cancer and the growing adoption of precision medicine. According to the World Health Organization, nearly 20 million new cancer cases were diagnosed worldwide in 2022, increasing the demand for accurate tissue-based diagnostic testing.
01 High cost of advanced diagnostic instruments and limited access The tissue diagnostics market faces challenges due to the high cost of advanced diagnostic instruments and limited access to specialized pathology services in developing regions. Automated immunohistochemistry, digital pathology scanners, and molecular tissue analysis platforms require significant capital investment, making adoption difficult for smaller laboratories.
01 Rapid expansion of precision oncology, AI-powered pathology, and companion diagnostics The tissue diagnostics market is expected to benefit from the rapid expansion of precision oncology, AI-powered pathology, and companion diagnostics. Growing investments in digital pathology infrastructure and biomarker discovery are creating new opportunities for diagnostic manufacturers and healthcare providers.
May 2026 Agilent Technologies introduced new digital pathology workflow enhancements integrating AI-assisted image analysis with its pathology solutions, strengthening end-to-end tissue diagnostics capabilities for clinical laboratories and cancer research centers.
March 2026 Roche Diagnostics expanded its companion diagnostics portfolio through additional regulatory approvals for VENTANA tissue assays supporting precision oncology and biomarker-driven cancer treatment selection.
January 2026 Danaher – Leica Biosystems launched an upgraded BOND-PRIME staining workflow featuring enhanced automation, optimized reagent management, and improved throughput for immunohistochemistry (IHC) tissue diagnostics laboratories.
October 2025 Roche Diagnostics expanded its VENTANA DP 600 slide scanner software capabilities by introducing AI-enabled digital pathology workflow enhancements, improving tissue image analysis and integration with pathology laboratories.